Dicerna Pharmaceuticals Stock Forecast, Price & News

Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions

Is Dicerna Pharmaceuticals a buy right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 9 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Dicerna Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DRNA, but not buy additional shares or sell existing shares.
View analyst ratings for Dicerna Pharmaceuticals or view top-rated stocks.

How has Dicerna Pharmaceuticals' stock price been impacted by Coronavirus?

Dicerna Pharmaceuticals' stock was trading at $16.88 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, DRNA stock has increased by 125.1% and is now trading at $37.99.
View which stocks have been most impacted by COVID-19.

Are investors shorting Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 2,880,000 shares, a drop of 32.4% from the October 31st total of 4,260,000 shares. Based on an average daily volume of 1,610,000 shares, the short-interest ratio is presently 1.8 days. Approximately 4.2% of the company's shares are sold short.
View Dicerna Pharmaceuticals' Short Interest.

When is Dicerna Pharmaceuticals' next earnings date?

Dicerna Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Dicerna Pharmaceuticals.

How were Dicerna Pharmaceuticals' earnings last quarter?

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) posted its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.22) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.41) by $0.19. Dicerna Pharmaceuticals had a negative net margin of 64.53% and a negative trailing twelve-month return on equity of 103.08%. During the same period last year, the business posted ($0.29) EPS.
View Dicerna Pharmaceuticals' earnings history.

What price target have analysts set for DRNA?

11 brokers have issued twelve-month price targets for Dicerna Pharmaceuticals' stock. Their forecasts range from $25.00 to $47.00. On average, they expect Dicerna Pharmaceuticals' share price to reach $34.06 in the next year. This suggests that the stock has a possible downside of 10.4%.
View analysts' price targets for Dicerna Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Dicerna Pharmaceuticals' key executives?

Dicerna Pharmaceuticals' management team includes the following people:

• Douglas M. Fambrough, President, Chief Executive Officer & Director
• James B. Weissman, Chief Operating Officer & Executive Vice President (LinkedIn Profile)
• Douglas W. Pagán, Chief Financial Officer
• Bob D. Brown, Chief Scientific Officer (LinkedIn Profile)
• Shreeram Aradhye, Chief Medical Officer & Executive Vice President (LinkedIn Profile)

What is Douglas M. Fambrough, Ph.D.'s approval rating as Dicerna Pharmaceuticals' CEO?

35 employees have rated Dicerna Pharmaceuticals CEO Douglas M. Fambrough, Ph.D. on Glassdoor.com. Douglas M. Fambrough, Ph.D. has an approval rating of 99% among Dicerna Pharmaceuticals' employees. This puts Douglas M. Fambrough, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Dicerna Pharmaceuticals' key competitors?

Some companies that are related to Dicerna Pharmaceuticals include Maravai LifeSciences (MRVI), Ono Pharmaceutical (OPHLF), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), United Therapeutics (UTHR), CureVac (CVAC), Ascendis Pharma A/S (ASND), Evotec (EVTCY), Legend Biotech (LEGN), Jazz Pharmaceuticals (JAZZ), Arrowhead Pharmaceuticals (ARWR), Biohaven Pharmaceutical (BHVN), Grifols (GRFS) and Zai Lab (ZLAB).
View all of DRNA's competitors.

What other stocks do shareholders of Dicerna Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Strongbridge Biopharma (SBBP), Amarin (AMRN), Exelixis (EXEL), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), Gilead Sciences (GILD), Pfizer (PFE) and Advanced Micro Devices (AMD).

What is Dicerna Pharmaceuticals' stock symbol?

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Who are Dicerna Pharmaceuticals' major shareholders?

Dicerna Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include RTW Investments LP (9.73%), BlackRock Inc. (7.41%), Morgan Stanley (2.23%), Assenagon Asset Management S.A. (1.74%), Maverick Capital Ltd. (1.68%) and Polar Capital Holdings Plc (1.67%). Company insiders that own Dicerna Pharmaceuticals stock include Adam Koppel, Bob D Brown, Douglas Fambrough, James B Weissman, John B Green, Karen Blasing, Ling Zeng, Marc D Kozin, Peter Kolchinsky, Regina M Paglia, Robert D Ciappenelli, Shreeram Aradhye and Stan Klimoff.
View institutional ownership trends for Dicerna Pharmaceuticals.

Which major investors are selling Dicerna Pharmaceuticals stock?

DRNA stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Eagle Asset Management Inc., Sumitomo Mitsui Trust Holdings Inc., Emerald Mutual Fund Advisers Trust, UBS Group AG, Granahan Investment Management Inc. MA, Artal Group S.A., and Parkman Healthcare Partners LLC. Company insiders that have sold Dicerna Pharmaceuticals company stock in the last year include Adam Koppel, Bob D Brown, James B Weissman, Karen Blasing, Ling Zeng, Regina M Paglia, Robert D Ciappenelli, Shreeram Aradhye, and Stan Klimoff.
View insider buying and selling activity for Dicerna Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Dicerna Pharmaceuticals stock?

DRNA stock was purchased by a variety of institutional investors in the last quarter, including Commodore Capital LP, EcoR1 Capital LLC, Great Point Partners LLC, Assenagon Asset Management S.A., Morgan Stanley, Two Sigma Advisers LP, Two Sigma Investments LP, and Voloridge Investment Management LLC. Company insiders that have bought Dicerna Pharmaceuticals stock in the last two years include Douglas Fambrough, and Marc D Kozin.
View insider buying and selling activity for Dicerna Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Dicerna Pharmaceuticals?

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dicerna Pharmaceuticals' stock price today?

One share of DRNA stock can currently be purchased for approximately $37.99.

How much money does Dicerna Pharmaceuticals make?

Dicerna Pharmaceuticals has a market capitalization of $2.96 billion and generates $164.31 million in revenue each year. The biopharmaceutical company earns $-112.75 million in net income (profit) each year or ($1.63) on an earnings per share basis.

How many employees does Dicerna Pharmaceuticals have?

Dicerna Pharmaceuticals employs 302 workers across the globe.

What is Dicerna Pharmaceuticals' official website?

The official website for Dicerna Pharmaceuticals is www.dicerna.com.

Where are Dicerna Pharmaceuticals' headquarters?

Dicerna Pharmaceuticals is headquartered at 33 HAYDEN AVENUE, LEXINGTON MA, 02421.

How can I contact Dicerna Pharmaceuticals?

Dicerna Pharmaceuticals' mailing address is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. The biopharmaceutical company can be reached via phone at (617) 621-8097, via email at [email protected], or via fax at 617-612-6298.